Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer

Sichuan University25 enrolled

Overview

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Carcinoma Esophagus Cancer

Interventions

Tumor antigen-sensitized DC vaccineBIOLOGICAL

subcutaneous administration

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically confirmed diagnosis of esophageal squamous cell carcinoma； * Immunotherapy for preoperative； * Karnofsky performance status 0-1; * The postoperative pathological stage is (y) Pt + and / or N + M0 according to AJCC 8th * Function of the main organs is normal; * Edition Patient's written informed consent Exclusion Criteria: * Tumor emergencies; * Abnormal coagulation function; * Contagious diseases, such as HIV, HBV, HCV infection; * Mental disorders; * Concomitant tumors; * Immunological co-morbidities

Locations (1)

West China Hospital

Chengdu, Sichuan, China

Outcomes

Primary Outcomes

Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0

Time frame: 3 months after the last administration of cells

Secondary Outcomes

Disease-free Survival

Number of participants with Disease-free Survival as assessed by RECIST1.1

Time frame: through study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.